Moreover, network pharmacology study showed Shuganjieyu capsule may affect 552 targets as well as MAPK pathway, TNF pathway, PI3K-Akt pathways, and so on in treatment of depression [73]. The gene discussed is AKT1; the disease is major depressive disorder.